NCT01544998View on ClinicalTrials.gov

Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2014

Conditions
Congestive Heart Failure
Interventions
DRUG

Nesiritide

10 ug/kg

DRUG

Tadalafil

5 mg

DRUG

Placebo

The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.

DRUG

Saline load

Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Trial Locations (1)

55902

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mayo Clinic

OTHER